financetom
Business
financetom
/
Business
/
Campari shares tumble more than 14% after results miss expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Campari shares tumble more than 14% after results miss expectations
Nov 3, 2024 2:44 PM

MILAN (Reuters) - Shares in Campari were down over 14% in early trading after the Italian spirits group missed analysts' third-quarter earnings expectations.

"Third quarter revenues missed expectations and there was no real update about the new CEO," said Angelo Meda, head of equities at Banor SIM.

Campari's results on Tuesday were well below analyst forecasts.

Net sales at maker of Aperol fell by 1.4% to 753 million euros ($816 million), while analysts expected a rise to 832 million, a Visible Alpha consensus showed.

Adjusted operating profit fell 18.2%.

CEO Matteo Fantacchiotti abruptly quit in September after only five months in charge, with the company citing personal reasons for his departure.

The company said on Tuesday it expected to conclude the search for a new CEO by the first half of next year.

($1 = 0.9224 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rheinmetall wants to take over German shipbuilder NVL, Bild reports
Rheinmetall wants to take over German shipbuilder NVL, Bild reports
Aug 27, 2025
BERLIN, Aug 27 (Reuters) - Defence group Rheinmetall wants to take over German shipbuilder Naval Vessels Luerssen, the German daily Bild reported on Wednesday, citing industry sources. According to Bild, the Luerssen family, who own the shipbuilder, plan to divest its military shipyards in Hamburg, Wilhelmshaven and Wolgast to focus on building megayachts. Rheinmetall's supervisory board intends to consider the...
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Aug 27, 2025
On Wednesday, Vor Bio Inc. announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN). IgA nephropathy, also known as Berger’s disease, is an autoimmune kidney disease where abnormal clumps of the antibody immunoglobulin A (IgA) deposit in the kidneys’...
Abercrombie & Fitch Lifts Full-Year Guidance as Second-Quarter Results Top Views
Abercrombie & Fitch Lifts Full-Year Guidance as Second-Quarter Results Top Views
Aug 27, 2025
01:20 PM EDT, 08/27/2025 (MT Newswires) -- Abercrombie & Fitch ( ANF ) upgraded its fiscal 2025 outlook on Wednesday after the apparel retailer's second-quarter results exceeded Wall Street's estimates, though earnings fell year over year. The company now expects full-year earnings between $10 and $10.50 per share, lifting the middle point versus its prior outlook of $9.50 to $10.50....
BRIEF-CCH Holdings Files For U.S IPO With SEC - SEC Filing
BRIEF-CCH Holdings Files For U.S IPO With SEC - SEC Filing
Aug 27, 2025
Aug 27 (Reuters) - CCH Holdings Ltd: * CCH HOLDINGS LTD - FILES FOR US IPO WITH SEC - SEC FILING * CCH HOLDINGS LTD - TO APPLY FOR NASDAQ LISTING UNDER SYMBOL 'CCHH' - SEC FILING * CCH HOLDINGS LTD: CATHAY SECURITIES INC IS UNDERWRITER TO IPO ;)) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved